Recent Updates
Recently added Catalysts
DVAX

Dynavax to Present at the 2019 Cantor Global Healthcare Conference

Key Takeaway: BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the 2019 Cantor Global Healthcare Conference on Friday, Oct. 4, at

Full Press Release Details

BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the 2019 Cantor Global Healthcare Conference on Friday, Oct. 4, at 12 p.m. E.T.
The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at http://investors.dynavax.com/events-presentations.
Dynavax is a biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers, develops and commercializes novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.  For more information, visit www.dynavax.com.

Contact Data

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.
Last updated: Sep 30, 2019